Literature DB >> 27067356

A novel troponin I rule-out value below the upper reference limit for acute myocardial infarction.

Susan M I Goorden1, Rudi A van Engelen2, Liza S M Wong2, Tjeerd van der Ploeg3, Gerard J E Verdel2, Madelon M Buijs1.   

Abstract

OBJECTIVE: To determine cut-off values for a recently introduced high sensitive cardiac troponin assay (hs-cTnI) which provide similar sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) for acute myocardial infarction (AMI) as known cut-off values for an hs-cTnT assay.
METHODS: A prospective observational study was performed. Hs-cTnT (Roche) and hs-cTnI (Abbott) were measured in consecutive patients with symptoms suggestive of AMI. Representative measurements (obtained at least 3 h after chest pain has started) and serial measurements with a time delay between 2.5 h and 4.5 h were used to determine cut-off levels. Two independent clinicians adjudicated the final diagnosis.
RESULTS: 1490 patients were included in the study of whom 114 (8%) received a final diagnosis of AMI. Receiver operating characteristics analysis showed no statistically significant differences in the areas under the curve between the two assays. Cut-off values for representative hs-TnI were found to be as follows: rule-out: 10 ng/L (sensitivity: 98.2%; 95% CI 95.7% to 100.0% and NPV: 99.8%; 99.5% to 100.0%); rule-in: 70 ng/L (specificity: 90.8%; 89.3% to 92.4% and PPV: 39.7%; 36.1% to 43.3%). For serial measurements we found a Δ rule-out cut-off value of 20 ng/L (sensitivity: 94.9%; 88.0% to 100.0% and NPV: 98.7%; 96.9% to 100.0%) and Δ rule-in cut-off values of 100 ng/L (specificity: 92.7%; 87.9% to 95.8% and PPV: 57.6%; 39.4% to 74.0%) and 300% (specificity: 93.8%; 90.4% to 97.2% and PPV: 61.3%; 51.1% to 71.5%).
CONCLUSIONS: Cut-off values for hs-cTnI measurements are determined which allow a similar diagnostic classification as compared with hs-cTnT. Importantly, for a rule-out paradigm this cut-off value is unmistakably lower than the upper reference limit. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27067356     DOI: 10.1136/heartjnl-2015-308667

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  4 in total

Review 1.  High-sensitivity assays for troponin in patients with cardiac disease.

Authors:  Dirk Westermann; Johannes Tobias Neumann; Nils Arne Sörensen; Stefan Blankenberg
Journal:  Nat Rev Cardiol       Date:  2017-04-06       Impact factor: 32.419

Review 2.  Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome.

Authors:  Andrew R Chapman; Kuan Ken Lee; David A McAllister; Louise Cullen; Jaimi H Greenslade; William Parsonage; Andrew Worster; Peter A Kavsak; Stefan Blankenberg; Johannes Neumann; Nils A Sörensen; Dirk Westermann; Madelon M Buijs; Gerard J E Verdel; John W Pickering; Martin P Than; Raphael Twerenbold; Patrick Badertscher; Zaid Sabti; Christian Mueller; Atul Anand; Philip Adamson; Fiona E Strachan; Amy Ferry; Dennis Sandeman; Alasdair Gray; Richard Body; Brian Keevil; Edward Carlton; Kim Greaves; Frederick K Korley; Thomas S Metkus; Yader Sandoval; Fred S Apple; David E Newby; Anoop S V Shah; Nicholas L Mills
Journal:  JAMA       Date:  2017-11-21       Impact factor: 56.272

3.  Serial high-sensitivity cardiac troponin T measurements to rule out acute myocardial infarction and a single high baseline measurement for swift rule-in: A systematic review and meta-analysis.

Authors:  M Arslan; A Dedic; E Boersma; E A Dubois
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2019-01-08

4.  High-Sensitivity Cardiac Troponin and the Risk Stratification of Patients With Renal Impairment Presenting With Suspected Acute Coronary Syndrome.

Authors:  Eve Miller-Hodges; Atul Anand; Anoop S V Shah; Andrew R Chapman; Peter Gallacher; Kuan Ken Lee; Tariq Farrah; Nynke Halbesma; James P Blackmur; David E Newby; Nicholas L Mills; Neeraj Dhaun
Journal:  Circulation       Date:  2017-10-04       Impact factor: 29.690

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.